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Abstract
Current therapeutics for hepatitis B virus (HBV) patients such as nucleoside analogs (NAs)
are effective; however, new antiviral drugs against HBV are still desired. Since the interac-
tion between the epsilon (ε) sequence of HBV pregenomic RNA and viral polymerase (Pol)
is a key step in the HBV replication cycle, we aimed to identify small compounds for its inhibi-
tion, and established a pull-down assay system for the detection of ε-RNA-binding-Pol.
Screening showed that 5 out of 3,965 compounds inhibited ε-Pol binding, and we identified
rosmarinic acid, which exhibited specificity, as a potential antiviral agent. In order to examine
the anti-HBV effects of rosmarinic acid, HBV-infected primary human hepatocytes from a
humanized mouse liver were treated with rosmarinic acid. The rosmarinic acid treatment
decreased HBV components including the amounts of extracellular HBV DNA with negligi-
ble cytotoxicity. We also investigated the combined effects of rosmarinic acid and the NA,
lamivudine. rosmarinic acid slightly enhanced the anti-HBV activity of lamivudine, suggest-
ing that the HBV replication step targeted by rosmarinic acid is distinct from that of NA. We
analyzed an additional 25 rosmarinic acid derivatives, and found that 5 also inhibited ε-Pol.
Structural comparisons between these derivatives implied that the “two phenolic hydroxyl
groups at both ends” and the “caffeic acid-like structure” of rosmarinic acid are critical for the
inhibition of ε-Pol binding. Collectively, our results demonstrate that rosmarinic acid inhibits
HBV replication in HBV-infected cells by specifically targeting ε-Pol binding.
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Introduction
Hepatitis B virus (HBV) infection is a major health issue worldwide, with approximately 248 mil-
lion chronically infected individuals (CHB) [1]. Approximately 686,000 HBV-related deaths
occur annually [2]. Interferon-α (IFN-α), pegylated IFN-α (PEG-IFN-α), and six nucleos(t)ide
analogues (NAs), including lamivudine, entecavir, adefovir dipivoxil, tenofovir disoproxil fuma-
rate, tenofovir alafenamide, and telbivudine, are currently approved for use in the clinical treat-
ment of CHB patients [3]. Treatments with IFN have the potential to achieve HBsAg
seroclearance by immunomodulation; however, not all patients respond to IFN. Although NAs
more strongly suppress HBV replication than IFN by inhibiting reverse transcription (RT) with
less side effects, the discontinuation of NAs may result in the relapse of HBV. Thus, life-long
treatments with NAs are required, but may result in the emergence of resistant virus variants [4].
Since current therapeutics for CHB are insufficient, novel anti-HBV drugs are urgently required.
cccDNA serves as a template for all transcripts of HBV; therefore, it represents an attractive tar-
get for chronic HBV infection. Studies on zinc-finger nucleases (ZFNs), transcription activator-like
effector nucleases (TALENs), and RNA-guided clustered regulatory interspaced short palindromic
repeats (CRISPR)-Cas endonucleases were performed in order to specifically eliminate hepadna-
viral cccDNA [5–10]. The small compounds, CCC-0975 and CCC-0346, were identified as inhibi-
tors of the conversion from rcDNA to cccDNA [11]. However, their use as a clinical trial approach
is difficult because the strategy of targeting cccDNA is associated with the serious risk of side effects
due to off-targeting. Although many types of inhibitors targeting different replication steps, includ-
ing AT-61 and AT-130 (pregenomic RNA (pgRNA) encapsidation), Bay 41–4109 (capsid forma-
tion), nucleic acid polymers (multistep including secretion), and Myrcludex-B (entry), have been
identified [12–17], a novel drug has not yet been applied to clinical anti-HBV therapy.
HBV Pol functions in many essential steps of HBV replication including RT, DNA synthe-
sis, and RNA degradation. In addition to RT, the RNase H activity of Pol is a possible thera-
peutic target. Tavis and colleagues identified specific inhibitors for the RNase H activity of
HBV Pol [18–21]. Besides its enzymatic roles, HBV Pol is crucially involved in pgRNA encap-
sidation. HBV Pol interacts with the ε sequence of pgRNA, and the ε-Pol interaction is an
indispensable step for encapsidation [22]. Previous studies revealed that porphyrin com-
pounds including hemin suppressed the ε-Pol interaction and subsequent protein-priming
reaction [23]. Carbonyl J acid derivatives, known as HIV-1 RT inhibitors, have also been iden-
tified as ε-Pol binding and protein-priming inhibitors [24].
Since the interaction between ε and Pol is a distinct step from RT, ε-Pol binding inhibitors
may be promising agents for combination therapy with NAs. However, large-scale screening
to identify ε-Pol binding inhibitors has not yet been conducted. We herein established a
screening system to search for ε-Pol binding inhibitors, and performed it using three chemical
libraries including United States Food and Drug Administration (FDA)-, European Medicines
Agency (EMA)-, and other agency-approved compounds. As a result of screening, rosmarinic
acid and quercetin were identified as novel and specific inhibitors of ε-Pol binding. Quercetin
has been reported to inhibit HBV replication. Therefore, we analyzed the anti-HBV effects of
rosmarinic acid. Furthermore, an analysis of several types of rosmarinic acid derivatives
revealed the critical structural features of rosmarinic acid for the inhibition of ε-Pol binding.
Materials and methods
Cell culture and reagents
HEK-293T [25] and HepG2 [26] cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) (Nacalai Tesque, 08459) containing 10% fetal bovine serum (FBS), 100 U/
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ml penicillin, and 100 μg/ml streptomycin. Hep38.7-Tet cells [27] were maintained in DMEM
containing 5% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 400 μg/ml G418, and 400
ng/ml tetracycline. PXB-cells were purchased from PhoenixBio (PPC-P01) and cultured in
dHCGM (DMEM containing 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 20 mM
HEPES, 44 mM NaHCO3, 15 μg/ml L-proline, 250 ng/ml human recombinant insulin, 50 nM
dexamethazone, 5 ng/ml human recombinant epidermal growth factor (EGF), 100 μM ascor-
bic acid, and 2% DMSO).
Plasmids
p3×Flag CMV/pol (YE), an expression plasmid of 3×FLAG-Pol, was generated by Dr. Sakagu-
chi and Dr. Chayama (Hiroshima University, Japan). p3×FLAG-ISG20 was constructed as
described below. p3×Flag CMV/pol (YE) was digested using HindIII and EcoRI to remove the
cDNA of Pol, and subcloned ISG20 cDNA was then inserted into the cleaved vector. p3×FLA-
G-ISG20 D94G was generated using the KOD -plus- Mutagenesis Kit (TOYOBO, SMK101).
Nucleic acids
ε-biotin RNA, ε RNA, control-biotin RNA, and DNA-biotin were purchased from Japan Bio
Services. The sequence of ε RNA was 5'-ucucaUGUUCAUGUCCUACUGUUCAAGCCUCCAA
GCUGUGCCUUGGGUGGCUUUGGGGCAUGGACAuugac-3',and that of control RNA was
5'-ucucaUGACGAGGCUGGGUGCUCCUUCUACGUGUUUUCGUUGUAGGUAGGACCCAAA
UUGCCGCUCuugac-3' (Length and composition are the same as ε, whereas the sequence is
different [randomized]). The 5’ terminal “ucuca” and 3’ terminal “uugac” were 2’ O-Methyl
RNA (for stabilization). ε-biotin and control-biotin were biotinylated at the 3’ terminus. The
sequence of DNA-biotin was 5'-TCTCATGTTCATGTCCTACTGTTCAAGCCTCCAAGCTG
TGCCTTGGGTGGCTTTGGGGCATGGACATTGAC-3', and was biotinylated at the 3’ terminus.
Chemical libraries and compounds
The Tocriscreen compound library (Tocris Bioscience), Pharmakon1600 drug library (Micro-
source Discovery Systems), and Prestwick chemical library (Prestwick chemical) were used for
screening. The Pharmakon1600 drug library was generously provided by Dr. Koh Takeuchi
(Advanced Industrial Science and Technology, Ibaraki, Japan). The Prestwick chemical library
was kindly gifted by Dr. Masayuki Shimojima and Dr. Masayuki Saijo (National Institute of
Infectious Diseases, Tokyo, Japan). Rosmarinic acid, quercetin, merbromin, hemin, calcomine
orange 2RS, and salvianolic acid A were purchased from Sigma-Aldrich (536954, Q4951,
M7011, 51280-1G, C9519, and SML0045, respectively). Erythrosine B, and lamivudine were
purchased from Tokyo Chemical Industry (T0557 and L0217, respectively). Verteporfin was
purchased from Cayman Chemical (17334). Rosmarinic acid derivatives were synthesized as
previously described [28].
Compound treatment to cell lines stably expressing HBV
Hep38.7-Tet cells were seeded on collagen-coated 96-well plates at 1.0×104 cells/well. After cell
attachment (2 to 3 h), culture medium was replaced with fresh FBS-free medium containing
compounds 0, 1, 2, 3 days after seeding. FBS was added to culture medium 2 to 3 h after it had
been changed. On day 5, extracellular HBV DNA was extracted from the culture supernatant
and quantified by qPCR, as described below, and cells were then subjected to the WST-1 cell
proliferation assay (Takara, MK400) following the manufacturer’s instructions. CC50 in
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HepG2 cells was calculated from results at least 7 kinds of concentration of compound
(Table 1).
Compound treatment to primary human hepatocytes infected with HBV
PXB-cells were infected at 5 Geq/cell using dHCGM containing serum from HBV-infected
chimeric mice with humanized livers (PhoenixBio, PPC-BC), and 4% polyethylene glycol
8,000. Culture medium was replaced with fresh dHCGM containing compounds on days 1, 2,
and 7 post-infection. On days 7 or 12, extracellular HBV DNA was extracted from the culture
supernatant and quantified by qPCR, HBV RNA was extracted from cells and quantified by
RT-qPCR, and SHBs were measured by ELISA as described below.
Quantitative real-time PCR (qPCR)
Extracellular HBV DNA was extracted using the SMITEST EX-R+D KIT (Medical and Biolog-
ical Laboratories, GSJ0201) or Geno Plus Genomic DNA Extraction Miniprep System (Vio-
gene, GG2002). HBV DNA levels were monitored with the StepOnePlus Real Time PCR
System using the Fast SYBR PCR Master Mix (Applied Biosystems—Thermo Fisher Scien-
tific), and the following primer set: qPCR primers for HBV DNA (Forward 5'-TTCACCTCA
CCATACAGCACTC-3', Reverse 5'- ATAGGGGCATTTGGTGGTCTG-3'). The copy num-
ber/μl of HBV DNA was measured using the HBV DNA fragment, which was amplified by the
following primers: PCR primers for HBV DNA fragment amplification (Forward 5'-TTCA
CCTCACCATACAGCACTC-3', Reverse 5'- ATAGGGGCATTTGGTGGTCTG-3').
Quantitative real-time reverse transcription PCR (qRT-PCR)
Total RNA was isolated using TRIzol reagent (Invitrogen—Thermo Fisher Scientific,
15596018) with DNase I (Roche, 4716728), and subjected to RT using a High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems—Thermo Fisher Scientific, 4368813). mRNA
levels were quantified by the StepOnePlus Real Time PCR System using Fast SYBR PCR Mas-
ter Mix, and the following primer set: qRT-PCR primers for HBV RNA (Forward 5'-TTCAC
CTCACCATACAGCACTC-3', Reverse 5'- ATAGGGGCATTTGGTGGTCTG-3') and GAP
DH (Forward 5'- ACTGCCAACGTGTCAGTGGT-3', Reverse 5'- TTACTCCTTGGAGGC
CATGT-3').
Table 1. Citotoxicity of the compounds.













Rosmarinic acid inhibits ε-Pol binding
PLOS ONE | https://doi.org/10.1371/journal.pone.0197664 May 21, 2018 4 / 16
Enzyme-linked immunosorbent assay (ELISA)
Culture supernatants were analyzed using the HBs S Antigen Quantitative ELISA Kit, Rapid-II
(Beacle, Inc., BC013).
Electrophoresis mobility shift assay (EMSA)
EMSA was performed as described previously [29]. Briefly, a total of 30 pmol of the recombi-
nant RIG-I protein was mixed with 5 pmol of synthetic dsRNA (25/25c) [29] and in a reaction
mixture (20 mM Tris-HCl (pH 8.0), 1.5 mM MgCl2, and 1.5 mM DTT) in the presence of
compounds. After an incubation at room temperature for 15 min, the reaction mixture was
applied to a 15% acrylamide gel (TBE buffer) and dsRNA was detected by EtBr staining and
RIG-I by Coomassie Brilliant Blue staining.
Helicase assay
The RIG-I helicase assay was performed as described previously [29].
Pull-down assay
HEK-293T cells were transfected with p3×Flag CMV/pol (YE) or p3×FLAG-ISG20 D94G. At
48 h post-transfection, cells were harvested and stored at -80˚C. The cell pellet was lysed in
lysis buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% NP-40, 1 mM DTT, 2 μg/ml leupep-
tin, 1 mM PMSF, 1 mM vanadate, and 20 units of an RNase inhibitor) and centrifuged. The
cleared lysate was incubated in the presence of compounds on ice for 20 min, mixed with
RNAs (ε-biotin, ε, or control-biotin) and equilibrated with streptavidin sepharose (GE Health-
care, 17511301, GE Healthcare, Buckinghamshire, UK), incubated at 4˚C for 2 h with rotation,
collected by centrifugation, washed three times using lysis buffer, resuspended in SDS sample
buffer (125 mM Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 0.01% BPB, and 10% 2-mercap-
toethanol), incubated at 95˚C for 3 min, and then analyzed by SDS-PAGE using a 7.5% acryl-
amide gel and immunoblotting using an anti-FLAG-Peroxidase (HRP) antibody (Sigma-
Aldrich, A8592). The biotinylated DNA pull-down assay was performed as follows. One
microgram of DNA-biotin was incubated in the presence of compounds in buffer (50 mM
Tris-HCl (pH 8.0), 150 mM NaCl, and 1% NP-40), equilibrated with streptavidin sepharose at
4˚C for 2 h with rotation, collected by centrifugation, washed three times, and DNA was recov-
ered by extraction with TRIzol reagent. Recovered DNA was analyzed by 15% acrylamide gel
electrophoresis, followed by staining with EtBr.
Results
Screening of ε-Pol inhibitors by a pull-down assay
In order to identify novel inhibitors of ε-Pol binding, we established an in vitro screening sys-
tem based on a pull-down assay, as shown in Fig 1A. Briefly, chemically synthesized ε-biotin
RNA was mixed with chemicals in the lysates of human cell lines expressing 3×FLAG-tagged-
Pol, pulled down by streptavidin beads, and the ε-binding of 3×FLAG-Pol was then detected
by Western blotting. As expected, 3×FLAG-Pol was pulled down with ε-biotin, but not with
non-biotinylated ε or biotinylated RNA with an unrelated sequence (Fig 1B). Conditions were
optimized further by using the previously reported inhibitors, hemin and calcomine orange
2RS [23, 24] (Fig 1C), and we screened for novel inhibitors using chemical libraries.
Primary screening was performed using compounds in a 10-drug mix, and candidate inhib-
itors were eventually identified by secondary screening using a single compound in the candi-
date 10-drug mix (S1A and S1B Fig). As a result, 5 out of 3,965 compounds were identified as
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inhibitors of ε-Pol binding. All 5 compounds: rosmarinic acid, quercetin, erythrosine B, mer-
bromin, and verteporfin, exhibited inhibitory activities in dose-dependent manners (Fig 1D).
Of note, verteporfin is a porphyrin, similar to hemin.
Rosmarinic acid and quercetin are specific inhibitors of ε-Pol
We examined the specificities of the 5 compounds for the inhibition of ε-Pol. In order to
exclude the possibility that these compounds inhibit biotin-avidin binding, biotinylated DNA
was pulled down by streptavidin sepharose in the presence or absence of the compounds.
None of the 5 compounds affected binding between DNA-biotin and streptavidin sepharose
(Fig 2A), suggesting that these compounds target the protein-RNA interaction. A previous
study reported that RIG-I recognizes dsRNAs, such as the ε sequence in HBV pgRNA, and
subsequently exhibits anti-HBV activity [30]. In order to examine whether the compounds
identified affect RIG-I-dsRNA binding activity, we conducted an electrophoresis mobility shift
assay (EMSA) to investigate the interaction between dsRNA and RIG-I in the presence or
absence of the compounds. Rosmarinic acid and quercetin did not affect dsRNA-RIG-I bind-
ing, whereas the other compounds, erythrosin B, merbromin, and verteporfin, as well as the
previously reported chemicals, hemin and calcomine orange 2RS, inhibited dsRNA-RIG-I
binding (Fig 2B). We also tested whether the 5 compounds affect RIG-I helicase enzymatic
activity, and found that only rosmarinic acid and quercetin did not affect the helicase activity
Fig 1. Five ε-Pol binding inhibitors selected by pull-down assay-based screening. (A) Scheme of the detection of ε-Pol binding by pull-down assays. The lysate of
HEK-293T cells expressing 3×FLAG-Pol was incubated with ε-biotin, and pulled down using streptavidin sepharose. Precipitated 3×FLAG-Pol was detected by a
Western blot analysis using an anti-FLAG antibody. (B) A Western blot analysis for Pol pulled-down by the indicated RNAs (ε RNA with biotin, ε RNA without biotin,
and control RNA with biotin). (C and D) A Western blot analysis for Pol pulled-down by 10 pmol ε-biotin in the presence of the indicated compounds. Lamivudine was
used as a negative control. Arrows: bands detected at a position of the estimated mass of full-length 3×FLAG-Pol.
https://doi.org/10.1371/journal.pone.0197664.g001
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of RIG-I, suggesting that RIG-I signaling is not influenced by treatments with rosmarinic acid
and quercetin (S2A Fig). In order to further validate specificity, another RNP complex was
tested. Liu and colleagues recently reported that ISG20 interacted with ε in an enzymatic activ-
ity (exonuclease)-independent manner [31]. 3×FLAG-tagged ISG20 D94G, an exonuclease
inactive mutant, was pulled down with ε-biotin in the presence or absence of the compounds.
Rosmarinic acid and quercetin did not affect ε-ISG20 binding, whereas erythrosin B, merbro-
min, verteporfin, hemin, and calcomine Orange 2RS exerted inhibitory effects (Fig 2C). These
results suggest that rosmarinic acid and quercetin specifically inhibit the ε-Pol interaction.
Rosmarinic acid suppresses HBV replication
Quercetin was previously reported to inhibit HBV replication in HepG2.2.15 cells [32], a
HepG2-derived cell line stably expressing HBV. Thus, we focused on the anti-HBV activity of
rosmarinic acid using cell lines stably expressing HBV. No obvious cytotoxicity of rosmarinic
acid was observed up to 30 μM in HepG2 cells and Hep38.7-Tet cells, a tetracycline inducible
HBV-expressing cell line [27] (Fig 3B and 3D). The cytotoxicity of rosmarinic acid in HepG2
cells was also evaluated (Table 1). Hep38.7-Tet cells were treated with rosmarinic acid, and the
amount of HBV DNA secreted into the culture medium was quantified. The rosmarinic acid
treatment significantly decreased extracellular HBV DNA with rough estimation of EC50
Fig 2. Rosmarinic acid and quercetin are specific inhibitors of ε-Pol binding. (A) Seventy-one-base ssDNA-biotin was pulled-down in the presence of the
indicated compounds, and detected by EtBr staining. Arrow: 71-base ssDNA. (B) dsRNA-RIG-I EMSA in the presence of the indicated compounds. : monomeric
dsRNA, : dsRNA-RIG-I complex. (C) A Western blot analysis for ISG20 D94G pulled-down by ε-biotin in the presence of the indicated compounds. Arrow:
3×ISG20 D94G.
https://doi.org/10.1371/journal.pone.0197664.g002
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30 μM (Fig 3A). We then performed a combined treatment with rosmarinic acid and lamivu-
dine. Although a low concentration of lamivudine (10 nM) exerted weak anti-HBV effects, the
combined treatment enhanced inhibition (Fig 3C). PXB-cells, primary human hepatocytes iso-
lated from an immunodeficient mouse with a humanized liver, were subjected to HBV infec-
tion and the effects of rosmarinic acid on its replication were examined. Rosmarinic acid
showed no toxicity up to 100 μM (S3 Fig). Extracellular HBV DNA levels was significantly
reduced and intracellular HBV RNA and extracellular HBsAg levels were slightly reduced by
rosmarinic acid, suggesting that rosmarinic acid suppresses HBV replication in infected cells
(Fig 4A–4C). In PXB-cells, the combined treatment with rosmarinic acid and lamivudine did
Fig 3. Rosmarinic acid inhibits HBV DNA production in cell lines stably expressing HBV. Hep38.7-Tet cells were treated with rosmarinic acid at the indicated
concentrations, 100 nM lamivudine, or 400 ng/ml tetracycline (A and B), or with 30 μM rosmarinic acid and/or 10 nM lamivudine, 100 nM Lam, or 400 ng/ml
tetracycline (C and D). Five days after the induction of HBV expression, extracellular HBV DNA was quantified by qPCR (A and C), and cell viability was measured
using WST-1 reagent (B and D). Data are from one representative of at least two independent experiments; the means and S.D. of triplicate experiments are shown (:
p< 0.05, : p< 0.01, : p< 0.001).
https://doi.org/10.1371/journal.pone.0197664.g003
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not further enhance inhibition (Fig 4D–4F). Collectively, these results suggest that the ros-
marinic acid treatment suppresses HBV replication in infected cells. Of note, HBV-infected
PXB-cells were also treated with quercetin, and its inhibitory activity on HBV replication was
confirmed (S4A–S4C Fig). We analyzed the rosmarinic acid derivatives listed in Table 2. Sal-
vianolic acid A, Compound 2, 12c, 13c, and 21a [28] exhibited inhibitory activities against ε-
Pol binding in dose-dependent manners (Fig 5A). Similar to rosmarinic acid, these 5 deriva-
tives did not affect biotin-avidin binding, dsRNA-RIG-I binding, or RIG-I helicase activity
(Fig 5B, 5C and S2B Fig). Furthermore, these derivatives inhibited HBV DNA production at
similar levels to that of rosmarinic acid with low cytotoxicity (Fig 5D and Table 1). On the
other hand, other derivatives did not exhibit inhibitory activities (Fig 5E).
Discussion
In the present study, we established a pull-down assay to screen for inhibitors of HBV ε-Pol
binding. 3×FLAG-tagged full-length Pol was expressed in human cell lines, and cell lysates
were used in the assay. It was not necessary to include an exogenous chaperone protein to
detect the ε-Pol interaction. The ε-Pol interaction was detected in liver-derived (HepG2) and
non-liver (HEK-293T) cells. Due to its high transfection efficiency, we used HEK-293T cells
for screening. In order to test a larger number of chemicals, we mixed 10 compounds in pri-
mary screening. Although mixed chemicals may exhibit unexpected interference from each
other, we identified 5 out of 3,965 chemicals with inhibitory activities. Rosmarinic acid and
quercetin appeared to specifically inhibit the ε-Pol interaction.
Fig 4. Rosmarinic acid suppresses HBV replication in HBV-infected primary human hepatocytes. (A-C) PXB-cells were infected with HBV, and treated with 30 μM
rosmarinic acid or 500 nM lamivudine. Seven to 12 days post-infection, extracellular HBV DNA was quantified by qPCR, intracellular HBV 3.5 kb RNA was quantified
by RT-qPCR, and SHBs were measured by ELISA. (D-F) PXB-cells were infected with HBV, and were treated with 30 μM rosmarinic acid and/or 20 nM lamivudine.
Extracellular HBV DNA, intracellular HBV 3.5-kb RNA, and SHBs were measured as in (A-C). Data are from one representative of at least two independent
experiments; the means and S.D. of duplicate or triplicate experiments are shown ( p< 0.05,  p< 0.01). N.D.: not detected, n.s.: not significant.
https://doi.org/10.1371/journal.pone.0197664.g004
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In Fig 4E, PXB cells treated with rosmarinic acid had significantly lower intracellular 3.5kb
HBV RNA levels than DMSO-treated cells. Also, combined treatment with rosmarinic acid
and lamivudine had lower 3.5kb HBV RNA level. This observation was unexpected if rosmari-
nic acid solely targets ε-Pol interaction. However, HBV progenies produced from PXB cells
are known to have the potential to re-infect the cells. When rosmarinic acid specifically blocks
the epsilon-polymerase binding, the treatment is estimated to reduce the production level of
virus progenies and the rate of the secondary infection to PXB cells as well as to inhibit
cccDNA synthesis from the pre-genome 3.5 kb HBV RNA. In such a context, we assume that
HBV RNA levels in PXB cells were decreased by the treatment of rosmarinic acid.
Rosmarinic acid and quercetin are structurally related and both have two dihydoxybenzene
moieties (Fig 6A). We tested the derivatives of rosmarinic acid and found that some did not
exhibit inhibitory activities against the ε-Pol interaction. The examination with rosmarinic
acid and its derivatives revealed a relationship between its chemical structure and ε-Pol inhibi-
tion (Figs 5 and 6). Compounds with inhibitory activities commonly had two dihydoxyben-
zene moieties (Fig 6A); however, caffeic acid and its derivatives (C-4, -16a-k, -19, and -21b)
did not exhibit inhibitory activity. Comparisons between C-12c and C-11a revealed that the
two phenolic hydroxyl groups in the catechol structure were critical and the presence of 4
complete hydroxyl groups was required for inhibitory activity (compare C-12c with C-12a and
C12d). Similarly, modifications to the hydroxyl groups into–OCH3 groups (hydroxyl group
masked with CH3) resulted in the loss of inhibitory activity (compare C-12c with C-12b). On
the other hand, the linker structure connecting the two catechol structures appeared to be
Table 2. Rosmarinic acid derivatives.
Compound 2 (R)-2-(3,4-Dihydroxyphenyl)-1-carbamoylethyl
3-(3,4-dihydroxyphenyl)acrylate
Compound 3 Caffeic acid
Compound 4 Methyl caffeate
Compound 11a 2-Phenylethyl cinnamate
Compound 12a 2-(3,4-Dihydroxyphenyl)ethyl cinnamate
Compound 12b 2-(3,4-Dimethoxyphenyl)ethyl caffeate
Compound 12c 2-(3,4-Dihydroxyphenyl)ethyl caffeate
Compound 12d Phenylethyl caffeate
Compound 13a Phenylethyl 3-phenylpropanoate
Compound 13b 2-(3,4-Dihydroxyphenyl)ethyl 3-phenylpropanoate
Compound 13c 2-(3,4-Dihydroxyphenyl)ethyl
3-(3,4-dihydroxyphenyl)propanoate
Compound 13d 2-(3,4-Dimethoxyphenyl)ethyl 3-phenylpropanoate
Compound 16a 2-propenyl caffeate
Compound 16b Propyl caffeate
Compound 16c Butyl caffeate
Compound 16d Pentyl caffeate
Compound 16e Hexyl caffeate
Compound 16f Heptyl caffeate
Compound 16g Nonyl caffeate
Compound 16i 5-Hydroxypentyl caffeate
Compound 16k Hydroxyhexy caffeate
Compound 19 1-(3’,4’-Dihydroxyphenyl)non-1-en-3-one
Compound 21a N-caffeoyldopamine
Compound 21b Pentyl 1-(3’,4’-dihydroxyphenyl)propen amide
https://doi.org/10.1371/journal.pone.0197664.t002
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Fig 5. Rosmarinic acid derivatives also inhibit ε-Pol binding. (A) Western blot analysis for Pol pulled-down by ε-biotin in the presence of the
indicated compounds. Arrows: 3×FLAG-Pol. (B) ssDNA-biotin was pulled-down in the presence of the indicated compounds, and detected by
EtBr staining. Arrow: 71-base ssDNA. (C) dsRNA-RIG-I EMSA in the presence of the indicated compounds (100 μM). : monomeric dsRNA, :
the dsRNA-RIG-I complex. (D) Hep38.7-Tet cells were treated with 10 μM rosmarinic acid, compounds 12c, 13c, 2, and 21a, 100 nM lamivudine,
or 400 ng/ml tetracycline. Extracellular HBV DNA and cell viability were measured as in (Fig 3A and 3B). Data are from one representative of at
least two independent experiments; the means and S.D. of triplicate experiments are shown ( p< 0.05,  p< 0.01,  p< 0.001). (E) A Western
blot analysis for Pol pulled-down by ε-biotin in the presence of the indicated compounds. Arrows: 3×FLAG-Pol. Spliced images are indicated with
a dividing line.
https://doi.org/10.1371/journal.pone.0197664.g005
Fig 6. Chemical structures. Chemical structures of compounds with ε-Pol inhibitory activity (A), and without ε-Pol inhibitory activity (B).
https://doi.org/10.1371/journal.pone.0197664.g006
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flexible (compare C-12, C-2, C-13c, and C-21a). These results suggest that the 4 hydroxyl
groups in the two catechol structures at both side chain ends are critical “active domains” for
recognizing Pol. Whereas the linker structure was less critical for the specific interaction but
the linker may determine critical distance between the two active domains.
RIG-I is a viral RNA sensor for eliciting several antiviral responses [33, 34]. Previous studies
reported that innate immune signaling is important for anti-HBV responses [26, 30]. ISG20
was shown to inhibit HBV replication in nuclease-dependent and -independent manners [31,
35]. Since rosmarinic acid and quercetin inhibit ε-Pol binding without affecting dsRNA-RIG-I
binding, RIG-I helicase activity, or ε-ISG20 binding (Figs 1D, 2B and 2C and S2A Fig), they
presumably do not interfere with the host antiviral immune response.
Despite ε-Pol binding being strongly abolished by the rosmarinic acid treatment in vitro,
the suppression of HBV replication in cells by rosmarinic acid was less efficient than the nucle-
otide analogue, lamivudine. One of the reasons for insufficient inhibition is permeability.
Another potential reason is chemical stability in cells. These limitations may be overcome in
future studies. Rosmarinic acid is a natural compound (abundant in Lamiaceae herbs includ-
ing spearmint, sage, peppermint, and perilla) and is utilized as a dietary supplement as well as
Chinese herbal medicine. To date, no detrimental effects on humans have been reported, sug-
gesting lower toxicity in vivo. Therefore, if we optimize drug administration, we may be able to
evaluate the anti-HBV effects of rosmarinic acid in vivo.
Supporting information
S1 Fig. Pull-down assay-based screening for the search for novel ε-Pol binding inhibitors.
(A) A Western blot analysis for Pol pulled-down by ε-biotin in the presence of a chemical mix
containing 10 kinds of compounds. The final concentration of each compound was 30 μM. A
total of 3,965 compounds were screened. (B) Candidate mixes were divided into single com-
pounds, and analyzed as in (A). The final concentration of the compounds was 30 μM. Arrows:
3×FLAG-Pol.
(TIF)
S2 Fig. Effects of compounds on RIG-I helicase activity. The RIG-I helicase assay was con-
ducted in the presence of the indicated compounds. #: monomeric ssRNA, ##: annealed
dsRNA, (n.s.): non-specific band.
(TIF)
S3 Fig. Cytotoxicity of rosmarinic acid in HBV-infected primary human hepatocytes. PXB
cells were infected with HBV, and treated with Rosmarinic acid at indicated concentrations.
On day 12, cells were subjected to WST-1 cell proliferation assay. Data are from one represen-
tative of at least two independent experiments; means and S.D. of duplicate experiments are
shown.
(TIF)
S4 Fig. Quercetin suppresses HBV replication in HBV-infected primary human hepato-
cytes. PXB cells were infected with HBV, and treated with 30 μM Quercetin. Extracellular
HBV DNA, intracellular HBV 3.5 kb RNA, and SHBs were measured as in Fig 4A–4C. Data
are from one representative of at least three independent experiments; means and S.D. of
duplicate experiments are shown ( p< 0.05).
(TIF)
S5 Fig. Original gels and Western blots. Uncropped and unadjusted gels and Western blots.
(TIF)
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